Prognostic Significance of p27, Ki-67, and Topoisomerase IIα Expression in Clinically Nonfunctioning Pancreatic Endocrine Tumors

2000 ◽  
Vol 11 (3) ◽  
pp. 229-242 ◽  
Author(s):  
Hee Jin Chang ◽  
Kenneth P. Batts ◽  
Ricardo V. Lloyd ◽  
Thomas J. Sebo ◽  
Geoffrey B. Thompson ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Endocrine Tumors ◽  
Topoisomerase Iiα ◽  
Ki 67 ◽  
Pancreatic Endocrine Tumors

W1678 Will Ki-67 Predict Lymph Node Status in Pancreatic Endocrine Tumors?

2010 ◽  
Vol 138 (5) ◽  
pp. S-901-S-902
Author(s):  
Derick Christian ◽  
Amit S. Khithani ◽  
A. Joe Saad ◽  
Joshua G. Barton ◽  
Jeffrey D. Linder ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Status ◽  
Endocrine Tumors ◽  
Ki 67 ◽  
Node Status ◽  
Pancreatic Endocrine Tumors

Prognostic significance of Ki‐67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast

1999 ◽  
Vol 55 (1) ◽  
pp. 61-71 ◽  
Author(s):  
Pierre Rudolph ◽  
Gaëtan MacGrogan ◽  
Françoise Bonichon ◽  
Sven‐Olaf Frahm ◽  
Isabelle de Mascarel ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Prognostic Significance ◽  
Carcinoma Of The Breast ◽  
Topoisomerase Iiα ◽  
Ki 67 ◽  
Infiltrating Ductal Carcinoma

Prevalence and Prognostic Significance of Acinar Cell Differentiation in Pancreatic Endocrine Tumors

2002 ◽  
Vol 26 (7) ◽  
pp. 893-901 ◽  
Author(s):  
Rhonda K. Yantiss ◽  
Hee-Kyung Chang ◽  
Francis A. Farraye ◽  
Carolyn C. Compton ◽  
Robert D. Odze
Keyword(s):  
Cell Differentiation ◽  
Acinar Cell ◽  
Prognostic Significance ◽  
Endocrine Tumors ◽  
Pancreatic Endocrine Tumors

scholarly journals VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors

2009 ◽  
Vol 16 (4) ◽  
pp. 1219-1227 ◽  
Author(s):  
A M Schmitt ◽  
S Schmid ◽  
T Rudolph ◽  
M Anlauf ◽  
C Prinz ◽  
...  
Keyword(s):  
Glucose Transporter ◽  
Adverse Outcome ◽  
Hypoxia Inducible Factor ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Small Subset ◽  
Endocrine Tumors ◽  
Glucose Transporter 1 ◽  
Glut 1 ◽  
Pancreatic Endocrine Tumors

A small subset of familial pancreatic endocrine tumors (PET) arises in patients with von Hippel–Lindau syndrome and these tumors may have an adverse outcome compared to other familial PET. Sporadic PET rarely harbors somatic VHL mutations, but the chromosomal location of the VHL gene is frequently deleted in sporadic PET. A subset of sporadic PET shows active hypoxia signals on mRNA and protein level. To identify the frequency of functionally relevant VHL inactivation in sporadic PET and to examine a possible prognostic significance we correlated epigenetic and genetic VHL alterations with hypoxia signals. VHL mutations were absent in all 37 PETs examined. In 2 out of 35 informative PET (6%) methylation of the VHL promoter region was detected and VHL deletion by fluorescence in situ hybridization was found in 14 out of 79 PET (18%). Hypoxia inducible factor 1α (HIF1-α), carbonic anhydrase 9 (CA-9), and glucose transporter 1 (GLUT-1) protein was expressed in 19, 27, and 30% of the 152 PETs examined. Protein expression of the HIF1-α downstream target CA-9 correlated significantly with the expression of CA-9 RNA (P<0.001), VHL RNA (P<0.05), and VHL deletion (P<0.001) as well as with HIF1-α (P<0.005) and GLUT-1 immunohistochemistry (P<0.001). These PET with VHL alterations and signs of hypoxia signalling were characterized by a significantly shortened disease-free survival. We conclude that VHL gene impairment by promoter methylation and VHL deletion in nearly 25% of PET leads to the activation of the HIF-pathway. Our data suggest that VHL inactivation and consecutive hypoxia signals may be a mechanism for the development of sporadic PET with an adverse outcome.

scholarly journals Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

2007 ◽  
Vol 14 (2) ◽  
pp. 221-232 ◽  
Author(s):  
Eduardo Vilar ◽  
Ramón Salazar ◽  
Jose Pérez-García ◽  
Javier Cortes ◽  
Kjell Öberg ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Retrospective Studies ◽  
Response To Treatment ◽  
Biological Behavior ◽  
Endocrine Tumors ◽  
Ki 67 ◽  
Pancreatic Endocrine Tumors ◽  
Poorly Differentiated ◽  
Selection For

Neuroendocrine tumors (NETs) of the digestive tract are a heterogeneous group of rare malignancies. Three major subgroups can be defined: pancreatic endocrine tumors, carcinoid tumors, and poorly differentiated gastroenteropancreatic NETs. Classically, digestive NETS have been considered to have an indolent course characterized for prolonged stabilizations or slow progressions, but there are clear differences in terms of aggressiveness, clinical course, and response to treatment among them. Retrospective studies have identified several clinicopathological and immunohistochemical factors as angioinvasion and proliferative index assessed by Ki-67 expression, which predict biological behavior and correlate with survival. Chemotherapy regimens based on the combination of several active drugs such as streptozocin, doxorubicin, 5-fluorouracil, dacarbazine, and temozolomide show low response rates, which sets the need to improve the results of the medical treatment of these malignancies. This review will analyze the role of Ki-67 in digestive NETs under a clinical perspective and will suggest future fields for development of this approach that enable a better patient selection for chemotherapy. Also a comprehensive review of the literature about chemotherapy in NETs is presented.

scholarly journals Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients With Meningiomas

2020 ◽  
Vol 10 ◽  
Author(s):  
Yuki Kuranari ◽  
Ryota Tamura ◽  
Noboru Tsuda ◽  
Kenzo Kosugi ◽  
Yukina Morimoto ◽  
...  
Keyword(s):  
Prognostic Significance ◽  
Laboratory Data ◽  
Progression Free Survival ◽  
Cost Effective ◽  
Tumor Location ◽  
Neutrophil To Lymphocyte Ratio ◽  
Ki 67 ◽  
Who Grade ◽  
Lymphocyte Ratio ◽  
Subtotal Removal

BackgroundMeningiomas are the most common benign intracranial tumors. However, even WHO grade I meningiomas occasionally show local tumor recurrence. Prognostic factors for meningiomas have not been fully established. Neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic factor for several solid tumors. The prognostic value of NLR in meningiomas has been analyzed in few studies.Materials and MethodsThis retrospective study included 160 patients who underwent surgery for meningiomas between October 2010 and September 2017. We analyzed the associations between patients’ clinical data (sex, age, primary/recurrent, WHO grade, extent of removal, tumor location, peritumoral brain edema, and preoperative laboratory data) and clinical outcomes, including recurrence and progression-free survival (PFS).ResultsForty-four meningiomas recurred within the follow-up period of 3.8 years. WHO grade II, III, subtotal removal, history of recurrence, Ki-67 labeling index ≥3.0, and preoperative NLR value ≥2.6 were significantly associated with shorter PFS (P &lt; 0.001, &lt; 0.001, 0.002, &lt; 0.001, and 0.015, respectively). Furthermore, NLR ≥ 2.6 was also significantly associated with shorter PFS in a subgroup analysis of WHO grade I meningiomas (P = 0.003). In univariate and multivariate analyses, NLR ≥2.6 remained as a significant predictive factor for shorter PFS in patients with meningioma (P = 0.014).ConclusionsNLR may be a cost-effective and novel preoperatively usable biomarker in patients with meningiomas.

Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study

2003 ◽  
Vol 98 (11) ◽  
pp. 2435-2439 ◽  
Author(s):  
Lucio Gullo ◽  
Marina Migliori ◽  
Massimo Falconi ◽  
Paolo Pederzoli ◽  
Rossella Bettini ◽  
...  
Keyword(s):  
Clinical Study ◽  
Endocrine Tumors ◽  
Pancreatic Endocrine Tumors ◽  
Multicenter Clinical Study
Sign in / Sign up

Export Citation Format

Share Document